Scarica l'app Stockscreener
18.75
33.36%
4.69
Pre-mercato:
18.64
-0.11
-0.59%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$14.06
Aprire:
$19.07
Volume 24 ore:
16.11M
Relative Volume:
6.96
Capitalizzazione di mercato:
$1.93B
Reddito:
$70.85M
Utile/perdita netta:
$-324.22M
Rapporto P/E:
-4.9258
EPS:
-3.8065
Flusso di cassa netto:
$-277.36M
1 W Prestazione:
+37.77%
1M Prestazione:
-0.48%
6M Prestazione:
-23.22%
1 anno Prestazione:
+42.91%
Intervallo 1D:
$17.42
$20.00
Intervallo di 1 settimana:
$13.18
$20.00
Portata 52W:
$11.76
$34.29
Viridian Therapeutics Inc Stock (VRDN) Company Profile
Nome
Viridian Therapeutics Inc
Settore
Industria
Telefono
617.272.4600
Indirizzo
221 CRESCENT STREET, WALTHAM
Compare VRDN vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VRDN
Viridian Therapeutics Inc
|
18.75 | 1.93B | 70.85M | -324.22M | -277.36M | -3.8065 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Viridian Therapeutics Inc Stock (VRDN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-10 | Reiterato | Wedbush | Outperform |
| 2025-12-03 | Iniziato | William Blair | Outperform |
| 2025-11-24 | Iniziato | Truist | Buy |
| 2025-08-25 | Ripresa | Jefferies | Buy |
| 2024-12-19 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-11-25 | Iniziato | TD Cowen | Buy |
| 2024-09-11 | Reiterato | Needham | Buy |
| 2024-06-11 | Iniziato | Wolfe Research | Outperform |
| 2024-06-06 | Iniziato | Goldman | Buy |
| 2024-05-09 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2024-05-09 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2023-06-14 | Iniziato | BTIG Research | Buy |
| 2023-06-14 | Ripresa | Credit Suisse | Outperform |
| 2023-05-30 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-04-17 | Iniziato | Wells Fargo | Overweight |
| 2023-03-30 | Iniziato | Stifel | Buy |
| 2022-12-19 | Iniziato | Cowen | Outperform |
| 2022-12-19 | Iniziato | Needham | Buy |
| 2022-12-16 | Iniziato | Credit Suisse | Outperform |
| 2022-12-01 | Iniziato | H.C. Wainwright | Buy |
| 2022-06-23 | Iniziato | B. Riley Securities | Buy |
| 2021-11-18 | Iniziato | SVB Leerink | Outperform |
| 2021-10-12 | Iniziato | Evercore ISI | Outperform |
| 2021-01-25 | Iniziato | Ladenburg Thalmann | Buy |
Mostra tutto
Viridian Therapeutics Inc Borsa (VRDN) Ultime notizie
Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stock - BioSpace
5 Stocks Turning Heads With Double-Digit Gains - Insider Monkey
Viridian (VRDN) Climbs 33% on Looming Drug Commercialization - Insider Monkey
Viridian Therapeutics (VRDN) price target decreased by 11.71% to 36.18 - MSN
Viridian’s Reveal-2 beats expectations with elegrobart in TED - BioWorld News
Viridian soars on top-line phase 3 data for elegrobart in thyroid eye disease - Seeking Alpha
Viridian Therapeutics launches $250 million capital raise By Investing.com - Investing.com Canada
Viridian Therapeutics launches $250 million capital raise - Investing.com
Viridian eye disease drug surpasses expectations in late-stage trial; shares soar - Reuters
Jefferies raises Viridian Therapeutic stock price target on trial data - Investing.com
Wedbush Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $32 - Moomoo
VRDN: Veligrotug and elegrobart show strong efficacy in TED, with launch readiness and pipeline expansion - TradingView
Viridian Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Progress - BioSpace
Positive top-line Phase III results for Viridian’s elegrobart - The Pharma Letter
Viridian Therapeutics : REVEAL-2 Phase 3 Topline Results (Presentation) - marketscreener.com
Viridian’s elegrobart meets primary endpoint in chronic TED trial - Investing.com UK
PDUFA Decision Nears as Viridian Therapeutics (VRDN) Advances TED Pipeline and Reports Q1 Results - Yahoo Finance
Viridian Shares Climb As Trial Data Reinforces Position In Thyroid Eye Disease Market - Benzinga
VRDN Stock Reassessed As Analysts Cut Targets But Stay Bullish - timothysykes.com
Viridian Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Viridian Therapeutics stock surges on positive trial results By Investing.com - Investing.com Canada
Viridian Reports Positive Phase 3 Results in Thyroid Eye Disease - TipRanks
MSN Money - MSN
Elegrobart boosts Viridian (NASDAQ: VRDN) with strong Phase 3 TED trial win - Stock Titan
Earnings Flash (VRDN) Viridian Therapeutics, Inc. Reports Q1 Revenue $141,000 - marketscreener.com
Viridian Therapeutics (VRDN) deepens Q1 loss as late‑stage TED drugs progress - Stock Titan
Viridian (NASDAQ: VRDN) posts Q1 loss and advances TED drug approvals - Stock Titan
BRIEF-Viridian Therapeutics Q1 Revenue USD 6 Thousand Vs. IBES Estimate USD 27.5 Thousand - TradingView
Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease - Business Wire
Why (VRDN) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Jennison Associates LLC Makes New Investment in Viridian Therapeutics, Inc. $VRDN - MarketBeat
Wedbush Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $31 - Moomoo
Pictet Asset Management Holding SA Sells 126,618 Shares of Viridian Therapeutics, Inc. $VRDN - MarketBeat
Viridian Therapeutics (VRDN) soars 5.6%: Is further upside left in the stock? - MSN
Viridian Therapeutics (VRDN) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Viridian Therapeutics stock is tanking. Why the drop is linked to this Amgen study. - MSN
VRDN stock plummeted 41% pre-market today — what did its phase 3 active thyroid eye disease trial reveal? - MSN
Truist Reiterates Buy Rating for Viridian Therapeutics (VRDN) - Insider Monkey
Viridian plunges on topline late-stage results for elegrobart for thyroid eye disease - MSN
CapEx per share of Viridian Therapeutics, Inc. – FWB:1S1 - TradingView
Kopp Family Office Trims $3.5 Million Worth of Viridian Therapeutics Stake -- What Investors Should Know - AOL.com
Understanding Momentum Shifts in (VRDN) - Stock Traders Daily
Kopp Family Office Sells 117878 Shares of Viridian Therapeutics - HarianBasis.co
Viridian Therapeutics (VRDN) Stock Posts Double-Digit Growth Year-on-Year - Insider Monkey
Truist Adjusts Viridian Therapeutics Price Target Amid Sector Shifts - HarianBasis.co
Kopp Family Office Trims $3.5 Million Worth of Viridian Therapeutics Stake -- What Investors Should Know - The Motley Fool
Truist Financial Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Cuts Target Price to $33 - Moomoo
Viridian Therapeutics Inc Azioni (VRDN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.14%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):